Developer docs
API playgroundTry for free, no card

Search company profiles

Viroclinics Biosciences

Full company profile

uuid000iaoi

Namestring
Viroclinics Biosciences
Websiteurl
viroclinics.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Viroclinics Biosciences is a Netherlands-headquartered contract research and clinical laboratory services company based in Rotterdam, founded in 2000. The firm operates in the specialized virology and vaccine laboratory testing space, providing diagnostic and preclinical study services that typically support pharmaceutical and biotechnology sponsors in clinical trial and drug development programs. With 251-500 employees, it sits in the mid-sized specialty lab segment rather than competing as a generalist central laboratory.

The company's leadership team is anchored by co-founder and Chief Scientific Officer Albert Osterhaus, a globally recognized virologist whose scientific standing underpins the firm's virology specialization. Operations are led by CEO Bob van Gemen, with Hans Bunschoten as COO and David van Hoytema as CFO. The company remains privately held and is positioned within the broader preclinical assets market, which third-party research (The Business Research Company) sizes at $10.2 billion by 2030 with a 9.8% CAGR, providing a favorable industry tailwind for a specialty lab services provider.

The available data does not disclose specific product catalog details, pricing models, named customer relationships, revenue mechanics, or technology stack for Viroclinics specifically. A large share of the supplied source material pertains to Cerba Research rather than Viroclinics and is therefore not used to characterize the company. This data gap limits granularity on go-to-market execution, customer concentration, and product-level differentiation, and is itself an important finding for due diligence.

Short descriptiontext

Viroclinics Biosciences is a Rotterdam-based contract research organization founded in 2000 that provides diagnostic and preclinical virology and vaccine laboratory services to pharmaceutical and biotechnology sponsors.

Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersRotterdam, Netherlands
HQ citystring
Rotterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
contract research services, clinical laboratory services, virology testing, vaccine development, preclinical research
Industry3 codes
1Preclinical CROs (Discovery/Pharmacology/DMPK)
CodeHLAGAAABPrimaryYes
2Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
CodeHLAGAEABPrimaryNo
3Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
CodeHLAAAEAKPrimaryNo
NAICS code4 codes
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Contract Research & Clinical Laboratory Services
Social media profiles1 record
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Viroclinics Biosciences is a contract research and clinical laboratory services provider delivering diagnostic and preclinical study support for vaccine, antiviral, and infectious disease programs. Services span virology and vaccine laboratory testing, anatomic pathology and tissue analysis, flow cytometry, genomics, immunoassay, biomarker and bioanalytical solutions, pre-clinical study support, and central/specialty clinical trial laboratory logistics through a global laboratory network.

Differentiator
Functional benefit
Problem solved
Product and service14 records
1Anatomic Pathology & Tissue Analysis
CategorySpecialty Laboratory Services
Description

Specialty laboratory service covering digital imaging & analysis, immunohistochemistry (IHC), multiplex IHC & immunofluorescence, in-situ hybridization (ISH), and spatial omics (Nanostring GeoMx) for clinical trial and research use.

2Assay Development & Technology Transfer
CategorySpecialty Laboratory Services
Description

Service for developing custom laboratory assays and transferring assay technology to support clinical trial and research programs.

3Bioanalytical Solutions
CategorySpecialty Laboratory Services
Description

Bioanalytical testing services supporting drug development and clinical research.

4Biomarker Solutions
CategorySpecialty Laboratory Services
Description

Biomarker testing and development services for clinical trials and translational research.

5Flow Cytometry Services
CategorySpecialty Laboratory Services
Description

Flow cytometry panels and biomarkers, custom assay development, scientific project management, and reporting services for clinical trials and research.

6Genomics Services
CategorySpecialty Laboratory Services
Description

Genomics capabilities including constitutional genomics, DNA/RNA extraction, genomics for infectious diseases, immune repertoire sequencing, and next-generation sequencing for solid tumors, hematological malignancies, and liquid biopsies.

7Immunoassay Services
CategorySpecialty Laboratory Services
Description

Immunoassay laboratory testing for clinical trials and research programs.

8Pre-clinical Services
CategoryPreclinical Research Services
Description

Preclinical research services supporting drug and vaccine development programs prior to clinical trials.

9Pre-Analytical and PBMC Processing
CategorySpecialty Laboratory Services
Description

Sample pre-analytical processing and peripheral blood mononuclear cell (PBMC) processing for clinical and research use.

10Virology & Vaccine Laboratory Services
CategorySpecialty Laboratory Services
Description

Dedicated virology and vaccine laboratory services for vaccine, antiviral, and infectious disease development programs.

11Central & Specialty Clinical Trial Laboratory Solutions
CategoryCentral Laboratory Services
Description

Central and specialty laboratory services for clinical trials across multiple therapeutic areas, including project management, protocol development, safety testing, and logistics.

12Biotech Lab Solution
CategoryCentral Laboratory Services
Description

Central laboratory solution tailored to biotech sponsors running clinical trials.

13Global Laboratory Network
CategoryCentral Laboratory Services
Description

Network of 42+ laboratories spanning five continents delivering specialty and central lab solutions for clinical trials globally.

14Specialty Diagnostic Kits
CategoryCentral Laboratory Logistics
Description

Distribution of specialty diagnostic kits as part of central laboratory logistics for clinical trials.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-01
Description

US-based AbbVie extended its partnership with India's Calibr to jointly advance preclinical and early clinical assets. Calibr is part of Scripps Research. This partnership is mentioned in general preclinical market context, not as a Viroclinics partnership.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-01
Description

Calibr operates within the Scripps Research ecosystem. AbbVie's partnership with Calibr builds on an existing relationship with Scripps Research. This is general market information, not Viroclinics-specific.

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CRO with central and specialty laboratory services supporting vaccine and infectious-disease clinical trials, an overlap with Viroclinics' clinical virology lab capabilities.

TypeBroad incumbent
Description

International laboratory services group with dedicated clinical trial and pharma testing offerings including virology and vaccine assays, broadly comparable in lab-services model.

TypeBroad incumbent
Description

Global central and specialty lab services within a diversified CRO/Central lab platform; provides virology and vaccine trial support comparable to Viroclinics, alongside much broader offerings.

TypeDirect peer
Description

Clinical lab services joint venture (IQVIA/Quest) providing specialty biomarker, immunoassay, flow cytometry and vaccine/virology testing for clinical trials — highly comparable specialty lab peer.

TypeBroad incumbent
Description

Large preclinical CRO and specialty lab services provider with virology, vaccine and biologics safety testing capabilities, competing for many of the same preclinical and lab-service engagements as Viroclinics.

TypeDirect peer
Description

Specialty clinical laboratory focused on infectious disease, immunology, and vaccine-related testing for clinical trials and transplant services — directly comparable to Viroclinics' virology and vaccine specialty lab offering.

TypeDirect peer
Description

Mid-size global CRO with laboratory and scientific services supporting vaccine and infectious-disease trials, comparable in scale and therapeutic focus.

TypeDirect peer
Description

Contract research and laboratory services organization providing preclinical, bioanalytical and specialty testing for biopharma — directly comparable as a mid-size specialty CRO/lab peer.

TypeBroad incumbent
Description

Global CRO with central and specialty lab services, including vaccine and infectious-disease trial support, comparable to Viroclinics' clinical-stage virology lab activities.

TypeBroad incumbent
Description

Global contract laboratory and clinical research services provider with vaccine and biologics testing capabilities, comparable as a broad-based lab services peer.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Viroclinics Biosciences

Contract Research & Clinical Laboratory Servicesviroclinics.com

Viroclinics Biosciences is a Rotterdam-based contract research organization founded in 2000 that provides diagnostic and preclinical virology and vaccine laboratory services to pharmaceutical and biotechnology sponsors.

What Viroclinics Biosciences does

Viroclinics Biosciences is a Netherlands-headquartered contract research and clinical laboratory services company based in Rotterdam, founded in 2000. The firm operates in the specialized virology and vaccine laboratory testing space, providing diagnostic and preclinical study services that typically support pharmaceutical and biotechnology sponsors in clinical trial and drug development programs. With 251-500 employees, it sits in the mid-sized specialty lab segment rather than competing as a generalist central laboratory.

The company's leadership team is anchored by co-founder and Chief Scientific Officer Albert Osterhaus, a globally recognized virologist whose scientific standing underpins the firm's virology specialization. Operations are led by CEO Bob van Gemen, with Hans Bunschoten as COO and David van Hoytema as CFO. The company remains privately held and is positioned within the broader preclinical assets market, which third-party research (The Business Research Company) sizes at $10.2 billion by 2030 with a 9.8% CAGR, providing a favorable industry tailwind for a specialty lab services provider.

The available data does not disclose specific product catalog details, pricing models, named customer relationships, revenue mechanics, or technology stack for Viroclinics specifically. A large share of the supplied source material pertains to Cerba Research rather than Viroclinics and is therefore not used to characterize the company. This data gap limits granularity on go-to-market execution, customer concentration, and product-level differentiation, and is itself an important finding for due diligence.

Viroclinics Biosciences firmographics

Firmographics
Name
Viroclinics Biosciences
Website
https://viroclinics.com
Company type
Private
Founded year
2000
Headcount range
251–500 employees
Short description
Viroclinics Biosciences is a Rotterdam-based contract research organization founded in 2000 that provides diagnostic and preclinical virology and vaccine laboratory services to pharmaceutical and biotechnology sponsors.
Ownership category
akta.pro rank

Viroclinics Biosciences industry classification

Industry
Product category
Contract Research & Clinical Laboratory Services
NAICS
Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro primary industry
Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
akta.pro secondary industries
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

Keywords

  • Contract research services
  • Clinical laboratory services
  • Virology testing
  • Vaccine development
  • Preclinical research

Where Viroclinics Biosciences is headquartered

Location

Headquarters

HQ city
Rotterdam
HQ country
Netherlands
HQ region
Europe

Markets served

Viroclinics Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Distribution channels1 record

Marketing channels5 records

Viroclinics Biosciences product offering

Product offering

Core offering

Viroclinics Biosciences is a contract research and clinical laboratory services provider delivering diagnostic and preclinical study support for vaccine, antiviral, and infectious disease programs. Services span virology and vaccine laboratory testing, anatomic pathology and tissue analysis, flow cytometry, genomics, immunoassay, biomarker and bioanalytical solutions, pre-clinical study support, and central/specialty clinical trial laboratory logistics through a global laboratory network.

Differentiator

Problem solved

Functional benefit

Products and services

  • Anatomic Pathology & Tissue Analysis Specialty laboratory service covering digital imaging & analysis, immunohistochemistry (IHC), multiplex IHC & immunofluorescence, in-situ hybridization (ISH), and spatial omics (Nanostring GeoMx) for clinical trial and research use.
  • Assay Development & Technology Transfer Service for developing custom laboratory assays and transferring assay technology to support clinical trial and research programs.
  • Bioanalytical Solutions Bioanalytical testing services supporting drug development and clinical research.
  • Biomarker Solutions Biomarker testing and development services for clinical trials and translational research.
  • Flow Cytometry Services Flow cytometry panels and biomarkers, custom assay development, scientific project management, and reporting services for clinical trials and research.
  • Genomics Services Genomics capabilities including constitutional genomics, DNA/RNA extraction, genomics for infectious diseases, immune repertoire sequencing, and next-generation sequencing for solid tumors, hematological malignancies, and liquid biopsies.
  • Immunoassay Services Immunoassay laboratory testing for clinical trials and research programs.
  • Pre-clinical Services Preclinical research services supporting drug and vaccine development programs prior to clinical trials.
  • Pre-Analytical and PBMC Processing Sample pre-analytical processing and peripheral blood mononuclear cell (PBMC) processing for clinical and research use.
  • Virology & Vaccine Laboratory Services Dedicated virology and vaccine laboratory services for vaccine, antiviral, and infectious disease development programs.
  • Central & Specialty Clinical Trial Laboratory Solutions Central and specialty laboratory services for clinical trials across multiple therapeutic areas, including project management, protocol development, safety testing, and logistics.
  • Biotech Lab Solution Central laboratory solution tailored to biotech sponsors running clinical trials.
  • Global Laboratory Network Network of 42+ laboratories spanning five continents delivering specialty and central lab solutions for clinical trials globally.
  • Specialty Diagnostic Kits Distribution of specialty diagnostic kits as part of central laboratory logistics for clinical trials.

Companies that use Viroclinics Biosciences

Customer profile

Ideal customer profiles1 record

Viroclinics Biosciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Viroclinics Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • CalibrcoreStrategic or Co-development Partner · 1 July 2023US-based AbbVie extended its partnership with India's Calibr to jointly advance preclinical and early clinical assets. Calibr is part of Scripps Research. This partnership is mentioned in general preclinical market context, not as a Viroclinics partnership.
  • Scripps ResearchcoreStrategic or Co-development Partner · 1 July 2023Calibr operates within the Scripps Research ecosystem. AbbVie's partnership with Calibr builds on an existing relationship with Scripps Research. This is general market information, not Viroclinics-specific.

Scale indicators1 record

Expansion highlights2 records

Viroclinics Biosciences competitors and assessment

Company assessment

Broad incumbents

  • ICON plc: Global CRO with central and specialty laboratory services supporting vaccine and infectious-disease clinical trials, an overlap with Viroclinics' clinical virology lab capabilities.
  • Eurofins Scientific: International laboratory services group with dedicated clinical trial and pharma testing offerings including virology and vaccine assays, broadly comparable in lab-services model.
  • Labcorp Drug Development (Covance): Global central and specialty lab services within a diversified CRO/Central lab platform; provides virology and vaccine trial support comparable to Viroclinics, alongside much broader offerings.
  • Charles River Laboratories: Large preclinical CRO and specialty lab services provider with virology, vaccine and biologics safety testing capabilities, competing for many of the same preclinical and lab-service engagements as Viroclinics.
  • PPD (Thermo Fisher Scientific): Global CRO with central and specialty lab services, including vaccine and infectious-disease trial support, comparable to Viroclinics' clinical-stage virology lab activities.
  • SGS Life Sciences: Global contract laboratory and clinical research services provider with vaccine and biologics testing capabilities, comparable as a broad-based lab services peer.

Direct peers

  • Q² Solutions: Clinical lab services joint venture (IQVIA/Quest) providing specialty biomarker, immunoassay, flow cytometry and vaccine/virology testing for clinical trials — highly comparable specialty lab peer.
  • Eurofins Viracor: Specialty clinical laboratory focused on infectious disease, immunology, and vaccine-related testing for clinical trials and transplant services — directly comparable to Viroclinics' virology and vaccine specialty lab offering.
  • Worldwide Clinical Trials: Mid-size global CRO with laboratory and scientific services supporting vaccine and infectious-disease trials, comparable in scale and therapeutic focus.
  • Frontage Laboratories: Contract research and laboratory services organization providing preclinical, bioanalytical and specialty testing for biopharma — directly comparable as a mid-size specialty CRO/lab peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Viroclinics Biosciences social profiles

Digital presence

Viroclinics Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Viroclinics Biosciences leadership team

Management profile

Number of profiles

Profiles4 records

Viroclinics Biosciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Viroclinics Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viroclinics Biosciences

What does Viroclinics Biosciences do?

Viroclinics Biosciences is a contract research and clinical laboratory services provider delivering diagnostic and preclinical study support for vaccine, antiviral, and infectious disease programs. Services span virology and vaccine laboratory testing, anatomic pathology and tissue analysis, flow cytometry, genomics, immunoassay, biomarker and bioanalytical solutions, pre-clinical study support, and central/specialty clinical trial laboratory logistics through a global laboratory network.

When was Viroclinics Biosciences founded?

Viroclinics Biosciences was founded in 2000. It employs 251 to 500 people.

Where is Viroclinics Biosciences based?

Viroclinics Biosciences is headquartered in Rotterdam, Netherlands, in the Europe region.

Who are Viroclinics Biosciences's main competitors?

Broad incumbents on record are ICON plc, Eurofins Scientific, Labcorp Drug Development (Covance), Charles River Laboratories, PPD (Thermo Fisher Scientific) and SGS Life Sciences. Direct peers are Q² Solutions, Eurofins Viracor, Worldwide Clinical Trials and Frontage Laboratories.

Does Viroclinics Biosciences have an API?

No public API is recorded for Viroclinics Biosciences.

What industry is Viroclinics Biosciences in?

Viroclinics Biosciences's product category is Contract Research & Clinical Laboratory Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 6215 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCaprion-HistoGeneX y Viroclinics-DDL anuncian una asociación estratégicaCaprion-HistoGeneX and Viroclinics-DDL announced a strategic partnership to provide integrated preclinical and clinical services for vaccine and antiviral therapeutic development targeting infectious diseases including COVID-19. The collaboration combines Caprion-HistoGeneX's immunology, proteomics, histopathology, and genomics expertise with Viroclinics-DDL's virology research, assay development, and clinical trial logistics capabilities. The combined entity will offer comprehensive services across all phases of vaccine and antiviral development through a global network spanning facilities in Canada, the United States, Belgium, the United Kingdom, Australia, China, and the Netherlands.PR NewswireDavide Molho, DVM Joins Viroclinics Biosciences as Chief Executive OfficerViroclinics Biosciences announced the appointment of Davide Molho, DVM as its new Chief Executive Officer, effective August 1, 2020, succeeding Bob van Gemen who had led the company since 2011. Dr. Molho joins from Evolution Research Group where he served as CEO, and previously spent nearly two decades at Charles River Laboratories, most recently as President and Chief Operating Officer. The new CEO will focus on revenue diversification into adjacent therapeutic fields and continued strategic expansion through acquisitions.PR NewswireViroclinics Biosciences et DDL Diagnostic Laboratory unissent leurs forcesViroclinics Biosciences announced the acquisition of DDL Diagnostic Laboratory to form a new group focused on virology research and diagnostic solutions for the global biopharmaceutical industry. The combined entity will operate from laboratories in Europe and China, leveraging a network of facilities across 20 countries to enhance capabilities in vaccine and antiviral trials. This strategic move aims to accelerate growth and expand service offerings for major biopharmaceutical clients.PR NewswireViroclinics Biosciences and DDL Diagnostic Laboratory Join ForcesViroclinics Biosciences, a leading virology contract research organization based in the Netherlands, has acquired DDL Diagnostic Laboratory, another Dutch-based diagnostic solutions provider, to strengthen the combined group's position in anti-viral and vaccine testing services. The transaction creates an organization operating four testing laboratories in Europe and China with access to a global network spanning 20 countries and a combined workforce of 240 specialized employees. Financial terms of the acquisition were not disclosed.PR NewswireParcom Capital Acquires Viroclinics BiosciencesParcom Capital has acquired Viroclinics Biosciences, a clinical research organization specializing in virology testing for vaccines and drugs in clinical trial stages prior to market launch. Viroclinics was founded in 2001, employs more than 100 experts, and serves clients globally including the world's top 10 biopharmaceutical companies, testing around 90 percent of all anti-influenza medications developed worldwide. The acquisition, with financial terms undisclosed, will support Viroclinics' growth ambitions including expansion into other viral targets such as hepatitis, polio, and RSV, while the company remains fully owned by Parcom Capital with no consequences for employees.FinSMEsViroclinics Biosciences Receives Majority Investment from Gilde Healthcare ServicesViroclinics Biosciences, a Dutch virology contract research organization, received a majority investment from Gilde Healthcare Services, with the deal amount undisclosed. The founding institute Erasmus University Medical Center exited the company. Viroclinics will use the proceeds to expand its service offerings and continue collaboration with Erasmus MC's Viroscience lab.